Literature DB >> 10652191

Elevation of vascular endothelial growth factor-A serum levels following acute myocardial infarction. Evidence for its origin and functional significance.

A Kranz1, C Rau, M Kochs, J Waltenberger.   

Abstract

Following the onset of acute myocardial infarction (AMI), a number of serum parameters show well-defined changes reflecting myocardial injury. During the consecutive repair phase, compensatory processes are initiated including the formation of a collateral circulation on the basis of angiogenesis and arteriogenesis. An important angiogenic factor is vascular endothelial growth factor-A (VEGF-A), shown to be upregulated in the ischemic myocardium. It is unclear, however, whether acute myocardial ischemia leads to a detectable elevation of VEGF-A serum concentrations. With the use of an immunoradiometric assay, we measured the levels of VEGF-A in the serum of patients after AMI at defined time intervals, of patients with unstable angina pectoris (UAP) and of healthy individuals. In addition, in a small group of patients with subacute myocardial infarction VEGF-A concentrations were measured in coronary sinus blood. The data are given as median followed by the 25th and 75th percentiles. In the group with AMI serum VEGF-A measured 105 [78; 176] pg/ml on day 1 and 114 pg/ml [72; 163] pg/ml on day 3 after onset of AMI. Serum levels of VEGF-A significantly increased on day 7 after AMI to 189 [119; 373] pg/ml (P=0.0103) and on day 10 to 255 [162; 371] pg/ml (P=0.0007). The VEGF-A serum level in healthy controls and in patients with UAP measured 98 [75; 137] pg/ml and 116 [57; 140] pg/ml, respectively. Serum at day 10 after AMI contained VEGF-A at a biologically relevant concentration capable of stimulating proliferation of endothelial cells. Surprisingly, VEGF-A serum levels were similar in samples taken from the coronary sinus with 61 [43; 83] pg/ml. Therefore the main source for VEGF-A in the blood stream is not the infarcted myocardium. However, the number of platelets, a rich source of VEGF-A, is significantly increased after myocardial infarction, i.e. 284 [252; 363] x 10(9)/litre v 220 [177; 250] x 10(9)/litre. In conclusion, the time course of VEGF-A elevation following AMI strongly suggests that VEGF-A plays a role as an endogenous activator of coronary collateral formation in the human heart. The most likely source of the elevated VEGF-A are platelets, rather than the infarcted myocardium. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10652191     DOI: 10.1006/jmcc.1999.1062

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  19 in total

Review 1.  The paracrine effect: pivotal mechanism in cell-based cardiac repair.

Authors:  Simon Maltais; Jacques P Tremblay; Louis P Perrault; Hung Q Ly
Journal:  J Cardiovasc Transl Res       Date:  2010-06-08       Impact factor: 4.132

Review 2.  Targeting angiogenesis to restore the microcirculation after reperfused MI.

Authors:  Anja M van der Laan; Jan J Piek; Niels van Royen
Journal:  Nat Rev Cardiol       Date:  2009-06-16       Impact factor: 32.419

3.  Changes in circulating mesenchymal stem cells, stem cell homing factor, and vascular growth factors in patients with acute ST elevation myocardial infarction treated with primary percutaneous coronary intervention.

Authors:  Y Wang; H E Johnsen; S Mortensen; L Bindslev; R Sejersten Ripa; M Haack-Sørensen; E Jørgensen; W Fang; J Kastrup
Journal:  Heart       Date:  2005-10-26       Impact factor: 5.994

4.  Analysis of progenitor cell mobilization and erythropoietin plasma levels in patients with acute myocardial infarction.

Authors:  Korff Krause; Boris Fehse; Kai Jaquet; Claudia Lange; Konstantin Kyriazis; Sigrid Boczor; Axel Zander; Karl-Heinz Kuck
Journal:  Exp Clin Cardiol       Date:  2005

5.  Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease.

Authors:  N A Chung; C Lydakis; F Belgore; F L Li-Saw-Hee; A D Blann; G Y H Lip
Journal:  Heart       Date:  2003-12       Impact factor: 5.994

Review 6.  Protein-, gene-, and cell-based therapeutic angiogenesis for the treatment of myocardial ischemia.

Authors:  Marc Ruel; Jianming Song; Frank W Sellke
Journal:  Mol Cell Biochem       Date:  2004-09       Impact factor: 3.396

7.  Stable phase post-MI patients have elevated VEGF levels correlated with inflammation markers, but not with atherosclerotic burden.

Authors:  Barbara ErŽen; Mira Šilar; Mišo Šabovič
Journal:  BMC Cardiovasc Disord       Date:  2014-11-22       Impact factor: 2.298

8.  Prognostic value of VEGF in patients submitted to percutaneous coronary intervention.

Authors:  Catarina Ramos; Patrícia Napoleão; Mafalda Selas; Cláudia Freixo; Ana Maria Viegas Crespo; Miguel Mota Carmo; Rui Cruz Ferreira; Teresa Pinheiro
Journal:  Dis Markers       Date:  2014-07-07       Impact factor: 3.434

9.  Identification of serum endoglin as a novel prognostic marker after acute myocardial infarction.

Authors:  Ignacio Cruz-Gonzalez; Pedro Pabón; Alicia Rodríguez-Barbero; Javier Martín-Moreiras; Miguel Pericacho; Pedro L Sánchez; Victor Ramirez; María Sánchez-Ledesma; Francisco Martín-Herrero; Javier Jiménez-Candil; Andrew O Maree; Angel Sánchez-Rodríguez; Cándido Martín-Luengo; José M López-Novoa
Journal:  J Cell Mol Med       Date:  2008-06       Impact factor: 5.310

Review 10.  Mesenchymal stem cells and neovascularization: role of platelet-derived growth factor receptors.

Authors:  Stephen G Ball; C Adrian Shuttleworth; Cay M Kielty
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.